Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Interventional × Fruquintinib × Clear all

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Conditions

Breast Neoplasms 6473 Neoplasms 4051 Prostatic Neoplasms 3153 Colorectal Neoplasms 2622 Carcinoma, Non-Small-Cell Lung 2509 Lung Neoplasms 2258 Leukemia, Myeloid, Acute 1747 Pancreatic Neoplasms 1688 Multiple Myeloma 1628 Carcinoma, Hepatocellular 1537 Neoplasm Metastasis 1400 Stomach Neoplasms 1346 Lymphoma 1321 Head and Neck Neoplasms 1273 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1269 Brain Neoplasms 1245 Ovarian Neoplasms 1212 Melanoma 1205 Leukemia 1186 Rectal Neoplasms 1121 Recurrence 1110 Colonic Neoplasms 1062 Glioblastoma 1031 Lymphoma, Non-Hodgkin 949 Uterine Cervical Neoplasms 946 Leukemia, Lymphocytic, Chronic, B-Cell 877 Esophageal Neoplasms 856 Lymphoma, Follicular 832 Lymphoma, Large B-Cell, Diffuse 821 Myelodysplastic Syndromes 809

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 HMPL-013 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Recruiting

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡